FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and includes pharmaceutical composition, which is solution of pharmaceutically acceptable substance 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine of formula (I) and D-mannitol in water. Composition is used for therapy of malignant tumors in human or animal.
EFFECT: technical result is obtaining stable, long-term stored solution of Substance 1.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| 6-SUBSTITUTED 3-AZOLYLIMIDAZO[1,2-b][1,2,4,5]TETRAZINES SHOWING ANTICANCER ACTIVITY | 2013 |
|
RU2527258C1 |
| 3-GUANIDINOAZOLO[1,2,4,5]TETRAZINES HAVING ANTIGLYCATING ACTIVITY AND A PROCESS FOR THEIR PREPARATION | 2017 |
|
RU2668971C1 |
| SUBSTITUTED AZOLO[1,2,4,5]TETRAZINES - INHIBITORS OF ANTIBACTERIAL SERINE-THREONINE PROTEIN KINASES | 2011 |
|
RU2462466C1 |
| 4-ISOPROPYL-6-R-IMIDAZO[1,2-B][1,2,4,5]TETRAZIN-3(4H)- ES WITH ANTIBACTERIAL ACTIVITY AGAINST NEISSERIA GONORRHOEAE | 2020 |
|
RU2754554C1 |
| 3-ISOPROPOXY-6-R-IMIDAZO[1,2-B][1,2,4,5]TETRAZINES HAVING ANTIBACTERIAL ACTIVITY AGAINST NEISSERIA GONORRHOEAE | 2020 |
|
RU2767869C1 |
| ANTITUBERCULOUS THERAPEUTIC AGENT: COMPOSITION OF IMIDAZO[1,2-b]TETRAZINE AND PYRAZINAMIDE | 2013 |
|
RU2545458C2 |
| ARYL-CONDENSED ISOSELENAZOLE COMPOUND CONTAINING TETRAZINE SUBSTITUTE, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2021 |
|
RU2818486C1 |
| SELECTIVE ANTIBACTERIAL AGENTS, REPRESENTED BY 3-(AZOL-1-YL)-6-AMINO-SUBSTITUTED 1,2,4,5-TETRAZINES | 2017 |
|
RU2642882C1 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY | 2006 |
|
RU2473560C2 |
